Article
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Scientific reports - 20 Feb 2020
Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James, Fu Siqing
Abstract excerpt
We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT01339871) or the proteasome inhibitor ixazomib (NCT02042989) in patients with metastatic TP53 mutant solid tumors. Both trials followed a 3 + 3 dose-escalation design allowing for a dose expansion cohort of up to 14 additional patients with a specific...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.